Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.


:The effects of liver disease on pharmacokinetics and pharmacodynamics are highly variable, and difficult to predict as the mechanisms of these effects are not well understood. Since the majority of the published literature is concerned with cirrhotic liver disease, this review also focuses mainly on this area. Four different theories have been proposed to account for the effects of chronic liver disease with cirrhosis on hepatic drug elimination: the sick cell theory; the intact hepatocyte theory; the impaired drug uptake theory; and the oxygen limitation theory. While some data in support of each of the first 2 theories have been published recently, a large amount of clinical data would appear to refute both of these theories. These clinical data are substantially consistent with the latter 2 theories, which regard the decreased permeability of the capillarised sinusoid as the critical feature in cirrhosis. Further work is required to determine the applicability of each of these theories. In cirrhosis, drug glucuronidation is spared relative to oxidative drug metabolism; however, in advanced cirrhosis this pathway may also be impaired substantially. There is evidence that in cirrhosis other conjugation pathways may also be impaired to variable degrees. Growing evidence suggests that biliary drug excretion is impaired in cirrhosis. Recent studies with several racemic drugs indicate that the disease can have different effects on the hepatic elimination of individual enantiomers, which may lead to a change in the concentration-response relationships of racemic drugs in cirrhosis. A major finding which has emerged in recent years is that, even with moderate degrees of hepatic impairment, there is a decrease in clearance of drugs or active metabolites normally cleared by the kidney. The effect on renal clearance of unbound drug may be masked if there is a concomitant decrease in plasma protein binding of the drug. Neither serum creatinine levels nor creatinine clearance are useful markers of the renal dysfunction associated with cirrhosis. Both may greatly overestimate renal function in patients with cirrhosis due to increased fractional renal tubular secretion of creatinine. Altered receptor sensitivity has been observed with some drugs in cirrhosis, while for other drugs there is no change in pharmacodynamics. Precise determination of drug dosage in cirrhosis requires information on changes in pharmacodynamics and plasma protein binding in addition to changes in drug elimination. Pharmacokinetic investigations in a variety of chronic liver diseases without cirrhosis (e.g. carcinoma, schistosomiasis and viral hepatitis) suggest that in the absence of cirrhosis, impairment of drug elimination is not sufficient to warrant reduction of drug dosage. However, if cirrhosis is present, 'safe' drug use requires an awareness of the possibility of multiple interactions between changes in hepatic and renal disposition and pharmacodynamics. In chronic liver disease with cirrhosis, dosage reduction is the general rule regardless of the route of elimination of drug or metabolite.


Clin Pharmacokinet


Morgan DJ,McLean AJ




Has Abstract


1995-11-01 00:00:00












  • Cardiovascular Risk Management and Hepatitis C: Combining Drugs.

    abstract::Direct-acting antivirals (DAAs) are known victims (substrate) and perpetrators (cause) of drug-drug interactions (DDIs). These DAAs are used for the treatment of hepatitis C virus (HCV) infections and are highly effective drugs. Drugs used for cardiovascular risk management are frequently used by HCV-infected patients...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Smolders EJ,Ter Horst PJG,Wolters S,Burger DM

    更新日期:2019-05-01 00:00:00

  • Effect of plasma exchange on the steady-state kinetics of digoxin and digitoxin.

    abstract::The pharmacokinetic effect of extracorporeal elimination can be evaluated from the extracorporeal elimination rate constant, from the amount of drug removed, and from extracorporeal clearance. To compare the validity of these approaches in clinical practice, the effect of multiple plasma exchanges on the steady-state ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章


    authors: Keller F,Kreutz G,Vöhringer HF,Offermann G,Distler A

    更新日期:1985-11-01 00:00:00

  • Clinical pharmacokinetics of fluvoxamine.

    abstract::Fluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression. Following oral administration, the drug is absorbed efficiently from the gastrointestinal tract. Peak plasma concentrations are usually observed within 2 to 8 hours postdose for capsules and film-coated tabl...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Perucca E,Gatti G,Spina E

    更新日期:1994-09-01 00:00:00

  • Cyclosporin clinical pharmacokinetics.

    abstract::Cyclosporin is a powerful immunosuppressive drug used in transplantation medicine and to treat autoimmune diseases. It is a lipophilic molecule, with its bioavailability dependent on food, bile and other interacting factors. Cyclosporin is extensively metabolised in the liver by the cytochrome P450 3A system, which is...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Fahr A

    更新日期:1993-06-01 00:00:00

  • Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations.

    abstract:BACKGROUND:Entecavir is an orally administered guanosine nucleoside analog with activity against hepatitis B virus (HBV) polymerase, which is approved for the treatment of chronic hepatitis B (CHB) infection in adults and children ≥2 years old (USA and EU). OBJECTIVE:To develop simplified entecavir dosing recommendati...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章


    authors: Chan P,Mould DR,Tarif MA,Reynolds L,LaCreta F,Bertz R,Bifano M

    更新日期:2016-12-01 00:00:00

  • A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.

    abstract:BACKGROUND:Peripherally acting opioids, particularly peripheral κ-opioid agonists, may be effective for treating visceral pain by activating receptors expressed on afferent nerves within the gut. OBJECTIVE:The objective of this study was to investigate the pharmacokinetic/pharmacodynamic profile of a novel peripherall...

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Olesen AE,Kristensen K,Staahl C,Kell S,Wong GY,Arendt-Nielsen L,Drewes AM

    更新日期:2013-02-01 00:00:00

  • Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.

    abstract::Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in the US, EU, and other regions for the treatment of adults with type 2 diabetes mellitus (T2DM). This review summarizes the ertugliflozin pharmacokinetic (PK) and pharmacodynamic data obtained during phase I clinical developm...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Fediuk DJ,Nucci G,Dawra VK,Cutler DL,Amin NB,Terra SG,Boyd RA,Krishna R,Sahasrabudhe V

    更新日期:2020-08-01 00:00:00

  • Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

    abstract::Histamine H2-receptor antagonists are a unique class of compounds. Pharmacologically they are characterised as a family by their ability to inhibit the secretion of gastric acid, and kinetically they are classified as a family by their similarity in absorption, distribution and elimination. All the H2-receptor antagon...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Lin JH

    更新日期:1991-03-01 00:00:00

  • Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations.

    abstract::It has been suggested that the minimum effective serum clozapine concentration for an acceptable clinical response (threshold value) is about 400 micrograms/L. This article argues against the use of therapeutic drug monitoring (TDM) as a tool to obtain clozapine concentrations of > or = 400 micrograms/L in the individ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Olesen OV

    更新日期:1998-06-01 00:00:00

  • Clinical pharmacokinetics of nabumetone. The dawn of selective cyclo-oxygenase-2 inhibition?

    abstract::Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthyl-alkanone class. Nabumetone is metabolised to an active metabolite 6-methoxy-2-napthylacetic acid (6-MNA) which is a relatively selective cyclo-oxygenase-2 inhibitor that has anti-inflammatory and analgesic properties. Nabumet...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Davies NM

    更新日期:1997-12-01 00:00:00

  • Clinical pharmacokinetics of drugs for Alzheimer's disease.

    abstract::Pharmacological treatment of patients with Alzheimer's disease is becoming more important, as evidenced by the number of drugs being developed in different countries. It has been shown in the majority of clinical trials that cholinesterase inhibitors, such as tacrine (tetrahydroaminoacridine), are able to induce benef...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Parnetti L

    更新日期:1995-08-01 00:00:00

  • Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.

    abstract:BACKGROUND AND OBJECTIVES:Upadacitinib is a janus kinase (JAK) 1 inhibitor being developed for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. This work characterized upadacitinib population pharmacokinetics in healthy subjects and RA patients and the effects of covariates on upadacitinib ex...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Klünder B,Mohamed MF,Othman AA

    更新日期:2018-08-01 00:00:00

  • Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus.

    abstract:BACKGROUND:Lorazepam is one of the preferred agents used for intravenous treatment of status epilepticus (SE). We combined data from two pediatric clinical trials to characterize the population pharmacokinetics of intravenous lorazepam in infants and children aged 3 months to 17 years with active SE or a history of SE....

    journal_title:Clinical pharmacokinetics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验


    authors: Gonzalez D,Chamberlain JM,Guptill JT,Cohen-Wolkowiez M,Harper B,Zhao J,Capparelli EV,Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.

    更新日期:2017-08-01 00:00:00

  • Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.

    abstract:BACKGROUND:Olaparib is a first-in-class potent oral poly(ADP-ribose) polymerase inhibitor. OBJECTIVES:The aims of this analysis were to establish an integrated population pharmacokinetic (PK) model of olaparib in patients with solid tumors and to bridge the PK of olaparib between capsule and tablet formulations. METH...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,meta分析


    authors: Zhou D,Li J,Bui K,Learoyd M,Berges A,Milenkova T,Al-Huniti N,Tomkinson H,Xu H

    更新日期:2019-05-01 00:00:00

  • Clinical pharmacokinetics of amiodarone.

    abstract::Amiodarone is an iodinated benzofuran derivative with recognised antiarrhythmic activity in man. As yet, its pharmacokinetic behaviour has not been satisfactorily characterised. Specific and sensitive high-pressure liquid chromatographic methods have become available only recently and this partly explains the scarcity...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Latini R,Tognoni G,Kates RE

    更新日期:1984-03-01 00:00:00

  • Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment.

    abstract:BACKGROUND:Enzyme replacement therapy (ERT) is currently the standard treatment for patients with Gaucher disease type I (GD1), but the pharmacokinetics have hardly been studied. This study aimed to quantify in vivo enzyme activity in peripheral leukocytes from patients receiving long-term treatment with imiglucerase o...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章


    authors: Gras-Colomer E,Martínez-Gómez MA,Moya-Gil A,Fernandez-Zarzoso M,Merino-Sanjuan M,Climente-Martí M

    更新日期:2016-09-01 00:00:00

  • Drug disposition in cystic fibrosis.

    abstract::There are many pathological changes in patients with cystic fibrosis (CF) which can lead to alterations in drug disposition. Although, in patients with CF, the extent of drug absorption varies widely and the rate of absorption is slower, bioavailability is not altered. Plasma protein binding for the majority of drugs ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Rey E,Tréluyer JM,Pons G

    更新日期:1998-10-01 00:00:00

  • Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

    abstract:BACKGROUND:Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. OBJECTIVE:To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertens...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,meta分析


    authors: Yoshihara K,Gao Y,Shiga H,Wada DR,Hisaoka M

    更新日期:2005-01-01 00:00:00

  • The efficiency concept in pharmacodynamics.

    abstract::The classic approach to describe the pharmacological response to a drug is to analyse its concentration-effect relationship, using a variety of possible models such as maximum effect (Emax) models or sigmoid Emax models. The aim of this review is to discuss an alternative way of describing the pharmacological effect i...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Alván G,Paintaud G,Wakelkamp M

    更新日期:1999-05-01 00:00:00

  • Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.

    abstract:BACKGROUND AND OBJECTIVE:Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects with chronic HCV infection. METHODS:A populati...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章


    authors: Chan P,Li H,Zhu L,Bifano M,Eley T,Osawa M,Ueno T,Hughes E,Bertz R,Garimella T,AbuTarif M

    更新日期:2017-10-01 00:00:00

  • Clinical pharmacokinetics of metformin.

    abstract::Metformin is widely used for the treatment of type 2 diabetes mellitus. It is a biguanide developed from galegine, a guanidine derivative found in Galega officinalis (French lilac). Chemically, it is a hydrophilic base which exists at physiological pH as the cationic species (>99.9%). Consequently, its passive diffusi...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Graham GG,Punt J,Arora M,Day RO,Doogue MP,Duong JK,Furlong TJ,Greenfield JR,Greenup LC,Kirkpatrick CM,Ray JE,Timmins P,Williams KM

    更新日期:2011-02-01 00:00:00

  • Clinical pharmacokinetics of fluconazole.

    abstract::Fluconazole was recently developed for the treatment of superficial and systemic fungal infections. Triazole groups and insertion of 2 fluoride atoms increase the polarity and hydrosolubility of the drug, allowing it to be used in a parenteral form. Bioassay methods using Candida pseudotropicalis as a test organism we...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Debruyne D,Ryckelynck JP

    更新日期:1993-01-01 00:00:00

  • Is there a concentration-effect relationship for sulphonylureas?

    abstract::Sulphonylureas have remained the mainstay of oral therapy for type 2 (non-insulin-dependent) diabetes mellitus (NIDDM). They stimulate insulin release from pancreatic beta cells. Pharmacokinetic differences between the various sulphonylureas are of clinical importance in terms of the time to onset of action, timing of...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Melander A,Donnelly R,Rydberg T

    更新日期:1998-03-01 00:00:00

  • Vigabatrin. Clinical pharmacokinetics.

    abstract::Vigabatrin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is supplied as a racemic mixture, with the S(+) enantiomer possessing pharmacological activity. [R,S]-Vigabatrin plasma concentrations can be estimated using high-performance liquid chromatographic methods. Only g...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Rey E,Pons G,Olive G

    更新日期:1992-10-01 00:00:00

  • Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.

    abstract::The pharmacokinetics and antihypertensive effects of felodipine, a new dihydropyridine calcium channel blocker, were studied in elderly hypertensive patients, 67 to 79 years of age and in young healthy subjects, 20 to 34 years of age following oral administration of 5 mg twice daily to steady-state. A single intraveno...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章


    authors: Landahl S,Edgar B,Gabrielsson M,Larsson M,Lernfelt B,Lundborg P,Regårdh CG

    更新日期:1988-06-01 00:00:00

  • Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.

    abstract:OBJECTIVE:To study the pharmacokinetics of micafungin in intensive care patients and assess pharmacokinetic (PK) target attainment for various dosing strategies. METHODS:Micafungin PK data from 20 intensive care unit patients were available. A population-PK model was developed. Various dosing regimens were simulated: ...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章


    authors: Martial LC,Ter Heine R,Schouten JA,Hunfeld NG,van Leeuwen HJ,Verweij PE,de Lange DW,Pickkers P,Brüggemann RJ

    更新日期:2017-10-01 00:00:00

  • Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

    abstract::Despite contributing significantly to the burden of global disease, the translation of new treatment strategies for diseases of the central nervous system (CNS) from animals to humans remains challenging, with a high attrition rate in the development of CNS drugs. The failure of clinical trials for CNS therapies can b...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Srinivas N,Maffuid K,Kashuba ADM

    更新日期:2018-09-01 00:00:00

  • Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

    abstract::Part I of this article, which appeared in the previous issue of the Journal, covered the following agents: histamine H2-receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine); muscarinic-M1-receptor antagonists (pirenzepine); proton pump inhibitors (omeprazole); site-protective agents (colloidal bismuth...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Lauritsen K,Laursen LS,Rask-Madsen J

    更新日期:1990-08-01 00:00:00

  • Pharmacokinetics of pancuronium in patients undergoing coronary artery surgery with and without low dose dopamine.

    abstract::Pancuronium is frequently used in coronary artery surgery, but its pharmacokinetics in these patients are still unknown. It is possible that dopamine, administered to prevent renal impairment induced by the surgery, might promote the elimination of pancuronium. Therefore, the pharmacokinetics of a bolus dose of pancur...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章


    authors: Wierda JM,van der Starre PJ,Scaf AH,Kloppenburg WD,Proost JH,Agoston S

    更新日期:1990-12-01 00:00:00

  • Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.

    abstract::Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. Nintedanib competitively binds to the kinase domains of vascular endothelial growth factor (VEGF), platelet-de...

    journal_title:Clinical pharmacokinetics

    pub_type: 杂志文章,评审


    authors: Wind S,Schmid U,Freiwald M,Marzin K,Lotz R,Ebner T,Stopfer P,Dallinger C

    更新日期:2019-09-01 00:00:00